Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Abstract Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor mutational burden (TMB) also being explored...

Full description

Bibliographic Details
Main Authors: Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau
Format: Article
Language:English
Published: BMJ Publishing Group 2019-02-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Checkpoint blockade
Predictive biomarkers
Oncogene
Neoantigens
T cells
Online Access:http://link.springer.com/article/10.1186/s40425-018-0492-x

Internet

http://link.springer.com/article/10.1186/s40425-018-0492-x

Similar Items